Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
E For L Aim PCLBKK:EFORL-R 40 Price-to-Operating-Cash-Flow is 12.00 as of Sep. 03, 2026, which is 111% above its 10-year median of 5.70. GuruFocus rates BKK:EFORL-R with a GF Score™ of 40/100 and a GF Value™ of ฿0.14 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 82 Medical Distribution companies, E For L Aim PCL ranks better than 54.88% on this metric.
As of today (2026-09-03), E For L Aim PCL's share price is ฿0.12.
E For L Aim PCL's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2026 was ฿0.01. Hence, E For L Aim PCL's Price-to-Operating-Cash-Flow Ratio for today is 12.00.
The historical rank and industry rank for E For L Aim PCL's Price-to-Operating-Cash-Flow or its related term are showing as below:
BKK:EFORL-R'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.58 Med: 5.7 Max: 2500
Current: 12
During the past 13 years, E For L Aim PCL's highest Price-to-Operating-Cash-Flow Ratio was 2500.00. The lowest was 1.58. And the median was 5.70.
BKK:EFORL-R's Price-to-Operating-Cash-Flow is ranked better than 54.88% of 82
companies
in the Medical Distribution industry
Industry Median: 12.235
vs BKK:EFORL-R: 12.00
E For L Aim PCL's Cash Flow from Operations per share for the
three
months ended in Jun. 2026 was ฿0.00.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2026 was ฿0.01.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of E For L Aim PCL was -78.30% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -19.70% per year.
During the past 13 years, E For L Aim PCL's highest 3-Year average Operating Cash Flow per Share Growth Rate was 72.00% per year. The lowest was -53.30% per year. And the median was -19.70% per year.
E For L Aim PCL Price-to-Operating-Cash-Flow Related Terms
E For L Aim PCL Price-to-Operating-Cash-Flow Historical Data
* Premium members only.
The historical data trend for E For L Aim PCL's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
E For L Aim PCL Price-to-Operating-Cash-Flow Chart
BKK:EFORL-R vs MCK, COR, CAH: Price-to-Operating-Cash-Flow Comparison
For the Medical Distribution subindustry, E For L Aim PCL's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
E For L Aim PCL Price-to-Operating-Cash-Flow vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, E For L Aim PCL's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where E For L Aim PCL's Price-to-Operating-Cash-Flow falls into.
E For L Aim PCL Price-to-Operating-Cash-Flow Calculation
E For L Aim PCL's Price-to-Operating-Cash-Flow ratio for today is calculated as
Price-to-Operating-Cash-Flow Ratio
=
Share Price
/
Cash Flow from Operations per share (TTM)
=
0.12
/
0.01
=
12.00
E For L Aim PCL's Share Price of today is ฿0.12. E For L Aim PCL's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Price-to-Operating-Cash-Flow of 12.00 mean?
E For L Aim PCL (BKK:EFORL-R) has a Price-to-Operating-Cash-Flow of 12.00 as of Sep. 03, 2026. Price-to-operating-cash-flow ratio is the ratio of share price to a company's per-share cash from operations. View historical data on E For L Aim PCL and its competitors. This is 111% above median its historical median of 5.70. Over the past decade, E For L Aim PCL's Price-to-Operating-Cash-Flow has ranged from 1.58 to 2,500.00. According to the industry distribution chart, E For L Aim PCL ranks #37 out of 82 companies in the Medical Distribution industry, placing it in the top 45.1%.
Is E For L Aim PCL's Price-to-Operating-Cash-Flow too high?
E For L Aim PCL's current Price-to-Operating-Cash-Flow of 12.00 is 111% above median its 10-year median of 5.70. Over the past 10 years, this metric has ranged from a low of 1.58 to a high of 2,500.00. The Medical Distribution industry median Price-to-Operating-Cash-Flow is 12.24. E For L Aim PCL's value of 12.00 is 1.9% below this industry median. Based on the distribution chart, E For L Aim PCL ranks #37 out of 82 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, E For L Aim PCL has a GF Score™ of 40/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does E For L Aim PCL's Price-to-Operating-Cash-Flow compare to MCK and COR?
According to the Medical Distribution industry distribution chart, E For L Aim PCL ranks #37 out of 82 companies for Price-to-Operating-Cash-Flow. This puts E For L Aim PCL in the upper half of its industry. The industry median Price-to-Operating-Cash-Flow is 12.24. E For L Aim PCL's value of 12.00 is 1.9% below this benchmark. Historically, E For L Aim PCL's own Price-to-Operating-Cash-Flow has ranged from 1.58 to 2,500.00 over the past decade. While the company's 10-year median is 5.70 vs. the industry median of 12.24, E For L Aim PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Operating-Cash-Flow for a Medical Distribution company?
The median Price-to-Operating-Cash-Flow among Medical Distribution companies is 12.24, based on 82 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Operating-Cash-Flow significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Operating-Cash-Flow should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. E For L Aim PCL's current Price-to-Operating-Cash-Flow of 12.00 is 1.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Operating-Cash-Flow mean?
A high Price-to-Operating-Cash-Flow can signal that a stock is expensive relative to its fundamentals. Price-to-operating-cash-flow ratio is the ratio of share price to a company's per-share cash from operations. View historical data on E For L Aim PCL and its competitors. For the Medical Distribution industry, the median Price-to-Operating-Cash-Flow is 12.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. E For L Aim PCL's current Price-to-Operating-Cash-Flow is 12.00, which is 111% above median its own 10-year median of 5.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is E For L Aim PCL stock overvalued right now?
Based on GuruFocus' analysis, E For L Aim PCL (BKK:EFORL-R) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿0.14, compared to a current price of ฿0.12 — trading 14.3% below its estimated fair value. The current Price-to-Operating-Cash-Flow is 12.00, which is 111% above median its 10-year median of 5.70 and 1.9% below the Medical Distribution industry median of 12.24. E For L Aim PCL's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Operating-Cash-Flow calculated?
Price-to-Operating-Cash-Flow is calculated from a company's financial statements. For E For L Aim PCL (BKK:EFORL-R), the current Price-to-Operating-Cash-Flow is 12.00 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is E For L Aim PCL (BKK:EFORL-R) Overvalued in 2026?
Based on GuruFocus' analysis, E For L Aim PCL stock appears to be undervalued.
The current stock price of ฿0.12 is trading 14.3% below its estimated GF Value™ of ฿0.14.
GuruFocus considers E For L Aim PCL to be Modestly Undervalued.
Key valuation signals for BKK:EFORL-R:
Price-to-Operating-Cash-Flow: 12.00 (111% above median its 10-year median of 5.70)
GF Value™: ฿0.14 vs. price of ฿0.12 (14.3% below fair value)
Industry Position: 1.9% below the Medical Distribution median (#37 of 82)
No single metric tells the full story. See the BKK:EFORL-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
E For L Aim PCL is engaged in the distribution of medical devices and equipment. The company and subsidiary have distributor agreements for medical devices and equipment with foreign companies. Its products include Patient Monitor System, Central Monitors System, Defibrillator, Automated External Defibrillator (AED), Electrocardiographs, Electroencephalogram (EEG), PSG System (Sleep Labs), and Accessories and Consumables. The group is principally engaged in one operating segment which is the distribution of medical device and equipment and providing service of medical equipment. Their operations are carried out in Thailand.
40GF Score
Get the complete analysis for BKK:EFORL-R
Price-to-Operating-Cash-Flow is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:EFORL-R has been successfully added to your 
